Table 2.
Characteristics of patient participants
| n = 158 (%) | |
|---|---|
| Demographics | |
| Age (years) | 64.5 (mean) (SD 10.80) |
| Sex | |
| Male | 108 (68.35%) |
| Female | 50 (31.65%) |
| Charlson co-morbidity index | 4 (mean) (SD 2.12) |
| WHO performance status | |
| 0 | 84 (53.16%) |
| 1 | 57 (36.08%) |
| 2 | 12 (7.59%) |
| 3 | 2 (1.27%) |
| Unknown | 3 (1.27%) |
| ASA | |
| 1 | 10 (6.33%) |
| 2 | 92 (58.23%) |
| 3 | 52 (32.91%) |
| 4 | 4 (2.53%) |
| Disease | |
| Benign | 13 (8.23%) |
| Malignant | 145 (91.77%) |
| Malignant subtype | 145 |
| Adenocarcinoma | 112 (77.2%) |
| Squamous cell carcinoma | 16 (11%) |
| GIST | 9 (6.2%) |
| Others | 7 (4.8%) |
| Unknown | 1 (0.7%) |
| Cancer stage | 128 |
| 1 | 15 (11.72%) |
| 2 | 45 (38.28%) |
| 3 | 51 (39.84%) |
| 4 | 9 (7.03%) |
| Unknown | 8 (6.25%) |
| Neoadjuvant therapy | |
| Chemotherapy | 64 (40.51%) |
| Chemoradiotherapy | 39 (24.68%) |
| Surgery alone | 55 (34.81%) |
SD standard deviation